Obesity: When to Consider Medication
Obesity: When to consider medication These 4 cases illustrate how weight loss drugs—including the 4 newest— can be integrated into a treatment plan that includes diet, exercise, and behavior modification Katherine H. Saunders, MD; Alpana P. Shukla, MD, MRCP; Leon I. Igel, MD; and Louis J. Aronne, MD odest weight loss of 5% to 10% Until recently, there were few pharma- among patients who are overweight cologic options approved by the US Food M or obese can result in a clinically and Drug Administration (FDA) for the relevant reduction in cardiovascular (CV) management of obesity. The mainstays of disease risk.1 This amount of weight loss can treatment were phentermine (Adipex-P, Ion- increase insulin sensitivity in adipose tissue, amin, Suprenza) and orlistat (Alli, Xenical). liver, and muscle, and have a positive impact Since 2012, however, 4 agents have been on blood sugar, blood pressure, triglycerides, approved as adjuncts to a reduced-calorie 1,2 and high-density lipoprotein cholesterol. diet and increased physical activity for long- IN THIS All patients who are obese or overweight term weight management.8,9 Phentermine/ ARTICLE with increased CV risk should be counseled topiramate extended-release (ER) (Qsymia) on diet, exercise, and other behavioral inter- and lorcaserin (Belviq) were approved Antiobesity 3 10,11 ventions. Weight loss secondary to lifestyle in 2012, and naltrexone sustained re- medication details modification alone, however, leads to adap- lease (SR)/bupropion SR (Contrave) and page 42 tive physiologic responses, which increase liraglutide 3 mg (Saxenda) were approved appetite and reduce energy expenditure.4–6 in 201412,13 (TABLE9,14–39).
[Show full text]